Last reviewed · How we verify

Grace Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Grace Therapeutics Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CaPre CaPre marketed cholestyramine Cardiovascular
GTX-104 GTX-104 phase 3 Immune checkpoint inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Brenda Cooper, MD · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. EMS · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. Glycotope GmbH · 1 shared drug class
  7. HK inno.N Corporation · 1 shared drug class
  8. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Grace Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Grace Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grace-therapeutics-inc. Accessed 2026-05-16.

Related